First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy
Raja Atreya, Ulrike Billmeier, Timo Rath, Jonas Mudter, Michael Vieth, Helmut Neumann, Markus F Neurath
Raja Atreya, Ulrike Billmeier, Timo Rath, Helmut Neumann, Markus F Neurath, Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, D-91054 Erlangen, Germany
Jonas Mudter, Medical Department, Hospital Ostholstein, 23701 Eutin, Germany
Michael Vieth, Institute of Pathology, Klinikum Bayreuth, 95445 Bayreuth, Germany
Author contributions: Atreya R and Neurath MF designed the study; Atreya R, Billmeier U, Rath T, Mudter J, Vieth M, Neumann H and Neurath MF acquired the data; Atreya R, Billmeier U, Vieth M, Neumann H, Neurath MF analyzed the data; Atreya R, Billmeier U, Rath T, Mudter J, Vieth M, Neumann H and Neurath MF interpreted the data and wrote the paper.
Supported by Clinical Research Group 257 CEDER of the Deutsche Forschungsgemeinschaft.
Institutional review board statement: Ethics approval has been granted by the Ethics Committee of the Friedrich-Alexander Universität Erlangen-Nürnberg. It has approved analysis of the mucosal biopsies. The anti-IL-6R antibody (tocilizumab) was applied as compassionate use therapy in a patient with treatment refractory ulcerative colitis.
Informed consent statement: The patient provided informed written consent prior to study enrolment.
Conflict-of-interest statement: The authors declare no conflict-of-interest
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Markus F Neurath, MD, Professor of Medicine, Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, D-91054 Erlangen, Germany. markus.neurath@uk-erlangen.de
Telephone: +49-9131-8535000 Fax: +49-9131-8535209
Received: March 29, 2015
Peer-review started: March 30, 2015
First decision: June 2, 2015
Revised: June 30, 2015
Accepted: September 14, 2015
Article in press: September 14, 2015
Published online: December 7, 2015
Processing time: 252 Days and 6.6 Hours
